Tecentriq® (atezolizumab): Risk of nephritis

User Rating: 1 / 5

Star ActiveStar InactiveStar InactiveStar InactiveStar Inactive


Healthcare professionals are informed of the new important identified risk of nephritis with use of Tecentriq® (atezolizumab).

Atezolizumab is indicated for the treatment of patients with metastatic non-small cell lung cancer who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have experienced disease progression on approved therapy for these aberrations prior to receiving atezolizumab.

It is recommended that atezolizumab be withheld for moderate (Grade 2) immune-related nephritis, and permanently discontinued for severe nephritis (Grade 3 and 4). Patients should be referred to a renal specialist, considering renal biopsy and supportive measures as indicated. Corticosteroids and/or additional immunosuppressive agents should be administered as clinically indicated.

A Direct Healthcare Professional Communication (DHPC) letter has been issued by Roche (M) Sdn. Bhd. in agreement with NPRA to highlight this safety issue. Please refer to this DHPC for further information.


National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti (Jalan Profesor Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075


The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Thursday 02 December 2021, 15:18:11.
© Copyright 2019 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA


Main Menu English

Choose Your Language